Automated and Closed Cell Therapy Processing Systems Market- Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Description
Market Overview
The Automated and Closed Cell Therapy Processing Systems Market is anticipated to grow significantly, expanding from USD 1,201.39 million in 2024 to an estimated USD 6,293.97 million by 2032. This reflects a strong compound annual growth rate (CAGR) of 23% over the forecast period.
Market expansion is driven by advancements in cell-based therapies, the rising emphasis on personalized medicine, and the increasing incorporation of automation within biomanufacturing processes. The surge in clinical trials and the global prevalence of chronic diseases are amplifying the demand for scalable, efficient manufacturing solutions. Additionally, the adoption of closed systems enhances safety and mitigates contamination risks, which is critical when producing sensitive cell-based therapeutics. These systems are increasingly vital to ensure quality, compliance, and consistency in cell therapy manufacturing.
Market Drivers
Technological Advancements in Cell Therapy Manufacturing
Innovation in manufacturing technologies plays a pivotal role in accelerating the adoption of automated and closed cell therapy processing systems. Automation enhances operational efficiency, scalability, and product safety—key factors in meeting the growing global demand for cell-based treatments. For example, in 2021, Thermo Fisher Scientific unveiled an automated platform aimed at scaling the production of cell and gene therapies, backed by a USD 300 million R&D investment. Furthermore, the U.S. Department of Energy allocated over USD 300 million toward advanced cell manufacturing initiatives, emphasizing automation as a strategic priority. These investments underscore the increasing focus on building robust, automated solutions to support the commercial viability of next-generation cell therapies.
Market Challenges
High Costs and Complex Manufacturing Demands
A major barrier to market growth lies in the substantial costs and complexity associated with developing and scaling automated cell therapy systems. These technologies require advanced infrastructure, skilled labor, and high-grade materials, all contributing to elevated capital and operational expenses. For emerging companies or startups, the financial commitment needed to implement such systems can be prohibitive. Moreover, manufacturing cell therapies involves intricate procedures that demand continuous R&D investment and strict compliance with evolving regulatory frameworks. Companies like Lonza face ongoing challenges balancing cost-efficiency with technological innovation. The need for investment in software, hardware, and process standardization further amplifies financial pressure. Although public and private funding initiatives aim to address these concerns, affordability and scalability remain key challenges, particularly for smaller market entrants seeking to remain competitive while maintaining quality and regulatory compliance.
Market Segmentation
By Product Type:
Automated Cell Therapy Processing Systems
Closed Cell Therapy Processing Systems
By Technology:
Automation Technology
Gene-Editing Technology
Stem-Cell Processing Technology
By End-User:
Hospitals
Research Institutions
Biotechnology Companies
Pharmaceutical Companies
By Region:
North America
United States
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Southeast Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Key Player Analysis
Miltenyi Biotec
Lonza
Fresenius Kabi AG
Danaher Corporation
BioSpherix, LLC
Terumo Corporation
Sartorius AG
ThermoGenesis Holdings, Inc.
CELLARS
Thermo Fisher Scientific Inc.
The Automated and Closed Cell Therapy Processing Systems Market is anticipated to grow significantly, expanding from USD 1,201.39 million in 2024 to an estimated USD 6,293.97 million by 2032. This reflects a strong compound annual growth rate (CAGR) of 23% over the forecast period.
Market expansion is driven by advancements in cell-based therapies, the rising emphasis on personalized medicine, and the increasing incorporation of automation within biomanufacturing processes. The surge in clinical trials and the global prevalence of chronic diseases are amplifying the demand for scalable, efficient manufacturing solutions. Additionally, the adoption of closed systems enhances safety and mitigates contamination risks, which is critical when producing sensitive cell-based therapeutics. These systems are increasingly vital to ensure quality, compliance, and consistency in cell therapy manufacturing.
Market Drivers
Technological Advancements in Cell Therapy Manufacturing
Innovation in manufacturing technologies plays a pivotal role in accelerating the adoption of automated and closed cell therapy processing systems. Automation enhances operational efficiency, scalability, and product safety—key factors in meeting the growing global demand for cell-based treatments. For example, in 2021, Thermo Fisher Scientific unveiled an automated platform aimed at scaling the production of cell and gene therapies, backed by a USD 300 million R&D investment. Furthermore, the U.S. Department of Energy allocated over USD 300 million toward advanced cell manufacturing initiatives, emphasizing automation as a strategic priority. These investments underscore the increasing focus on building robust, automated solutions to support the commercial viability of next-generation cell therapies.
Market Challenges
High Costs and Complex Manufacturing Demands
A major barrier to market growth lies in the substantial costs and complexity associated with developing and scaling automated cell therapy systems. These technologies require advanced infrastructure, skilled labor, and high-grade materials, all contributing to elevated capital and operational expenses. For emerging companies or startups, the financial commitment needed to implement such systems can be prohibitive. Moreover, manufacturing cell therapies involves intricate procedures that demand continuous R&D investment and strict compliance with evolving regulatory frameworks. Companies like Lonza face ongoing challenges balancing cost-efficiency with technological innovation. The need for investment in software, hardware, and process standardization further amplifies financial pressure. Although public and private funding initiatives aim to address these concerns, affordability and scalability remain key challenges, particularly for smaller market entrants seeking to remain competitive while maintaining quality and regulatory compliance.
Market Segmentation
By Product Type:
Automated Cell Therapy Processing Systems
Closed Cell Therapy Processing Systems
By Technology:
Automation Technology
Gene-Editing Technology
Stem-Cell Processing Technology
By End-User:
Hospitals
Research Institutions
Biotechnology Companies
Pharmaceutical Companies
By Region:
North America
United States
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Southeast Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Key Player Analysis
Miltenyi Biotec
Lonza
Fresenius Kabi AG
Danaher Corporation
BioSpherix, LLC
Terumo Corporation
Sartorius AG
ThermoGenesis Holdings, Inc.
CELLARS
Thermo Fisher Scientific Inc.
Table of Contents
197 Pages
- CHAPTER NO. 1 : INTRODUCTION
- 1.1.1. Report Description
- Purpose of the Report
- USP & Key Offerings
- 1.1.2. Key Benefits for Stakeholders
- 1.1.3. Target Audience
- 1.1.4. Report Scope
- CHAPTER NO. 2 : EXECUTIVE SUMMARY
- 2.1. Automated and Closed Cell Therapy Processing Systems Market Snapshot
- 2.1.1. Automated and Closed Cell Therapy Processing Systems Market, 2018 - 2032 (USD Million)
- CHAPTER NO. 3 : Automated and Closed Cell Therapy Processing Systems Market – INDUSTRY ANALYSIS
- 3.1. Introduction
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Market Opportunities
- 3.5. Porter’s Five Forces Analysis
- CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE
- 4.1. Company Market Share Analysis – 2023
- 4.2. Automated and Closed Cell Therapy Processing Systems Market Company Revenue Market Share, 2023
- 4.3. Company Assessment Metrics, 2023
- 4.4. Start-ups /SMEs Assessment Metrics, 2023
- 4.5. Strategic Developments
- 4.6. Key Players Product Matrix
- CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS
- CHAPTER NO. 6 : Automated and Closed Cell Therapy Processing Systems Market – BY Based on Product Type: ANALYSIS
- CHAPTER NO. 7 : Automated and Closed Cell Therapy Processing Systems Market – BY Based on Technology: ANALYSIS
- CHAPTER NO. 8 : Automated and Closed Cell Therapy Processing Systems Market – BY Based on End-User: ANALYSIS
- CHAPTER NO. 9 : Automated and Closed Cell Therapy Processing Systems Market – BY Based on Region: ANALYSIS
- CHAPTER NO. 10 : COMPANY PROFILES
- 9.1. Miltenyi Biotec
- 9.1.1. Company Overview
- 9.1.2. Product Portfolio
- 9.1.3. Swot Analysis
- 9.1.4. Business Strategy
- 9.1.5. Financial Overview
- 9.2. Lonza
- 9.3. Fresenius Kabi AG
- 9.4. Danaher Corporation
- 9.5. BioSpherix, LLC
- 9.6. Terumo Corporation
- 9.7. Sartorius AG
- 9.8. ThermoGenesis Holdings, Inc.
- 9.9. CELLARS
- 9.10. Thermo Fisher Scientific Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
